Pieris Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
Pieris Pharmaceuticals, Inc. carries a market capitalization of 17.96M, placing it among publicly traded companies globally. Its enterprise value stands at 1.95M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 17.96M |
| Enterprise Value | 1.95M |
Share Statistics
Pieris Pharmaceuticals, Inc. currently has 1.32M shares outstanding.
| Shares Outstanding | 1.32M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 402.09, and the price-to-book ratio stands at -0.07.
| PE Ratio | N/A |
| PS Ratio | 402.09 |
| PB Ratio | -0.07 |
| P/TBV Ratio | 1.31 |
| P/FCF Ratio | -2.56 |
| P/OCF Ratio | -2.56 |
Enterprise Valuation
| EV / Sales | 36.75 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Pieris Pharmaceuticals, Inc. maintains a current ratio of 4.82, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.82 |
| Quick Ratio | 4.76 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -28.46 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Pieris Pharmaceuticals, Inc.'s stock has declined approximately -4.96157% over the past 52 weeks. The 50-day moving average sits at 16.46, while the 200-day moving average is 14.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | -4.96157% |
| 50-Day Moving Average | 16.46 |
| 200-Day Moving Average | 14.03 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Pieris Pharmaceuticals, Inc. generated 53,000.00 in revenue and converted that into -11.37M in net income, yielding earnings per share of -8.85. EBITDA reached -12.64M, while operating income came in at -12.61M.
| Revenue | 53,000.00 |
| Gross Profit | N/A |
| Operating Income | -12.61M |
| Pretax Income | -11.37M |
| Net Income | -11.37M |
| EBITDA | -12.64M |
| EBIT | -12.61M |
| Earnings Per Share (EPS) | -8.85 |
Balance Sheet
Total book value stands at -326.33M, with working capital of 16.27M providing operational flexibility.
| Cash & Cash Equivalents | 19.36M |
| Total Debt | N/A |
| Net Debt | -19.36M |
| Equity (Book Value) | -326.33M |
| Book Value Per Share | -253.89 |
| Working Capital | 16.27M |
Cash Flow
Pieris Pharmaceuticals, Inc. produced -8.33M in operating cash flow over the past twelve months.
| Operating Cash Flow | -8.33M |
| Capital Expenditures | N/A |
| Free Cash Flow | -8.33M |
| FCF Per Share | -6.48 |
Margins
Pieris Pharmaceuticals, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -23,801.89 and net profit margin of -21,450.94 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -23,801.89 |
| Pretax Margin | -21,450.94 |
| Profit Margin | -21,450.94 |
| EBITDA Margin | -23,858.49 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -39.09 |
Stock Splits
Pieris Pharmaceuticals, Inc.'s most recent stock split took place on April 23, 2024 with a 80:1 split ratio.
| Last Split Date | 4/23/2024 |
| Split Ratio | 80:1 |
Scores
Pieris Pharmaceuticals, Inc. posts an Altman Z-Score of -20.33, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -20.33 |